Discover
ARMP
Armata Pharmaceuticals, Inc.
4.18
100 x 4.16
100 x 4.27
bid
ask
+
0.08
1.95%
100 @ 07:31 PM
4.16 -0.02 (0.48%)
| Ytd | -33.44% | |
| 1y | 40.27% |
4.01
day range
4.40
2.95
52 week range
14.80
| Open | 4.07 | Prev Close | 4.10 | Low | 4.01 | High | 4.40 | Mkt Cap | 155.42M |
| Vol | 160.61K | Avg Vol | 245.80K | EPS | -5.29 | P/E | N/A | Forward P/E | -1.30 |
| Beta | 0.81 | Short Ratio | 0.86 | Inst. Own | 3.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 4.86 | 200-d Avg | 7.42 | 1yr Est | 7.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-13 | 2024-09 | -0.28 | -0.15 | 0.13 | 46.43% |
| 2024-08-13 | 2024-06 | -0.52 | -0.65 | -0.13 | -25.00% |
| 2024-05-07 | 2024-03 | -0.28 | -0.69 | -0.41 | -146.43% |
| 2024-03-21 | 2023-12 | 0 | -0.55 | N/A | N/A |
| 2023-11-14 | 2023-09 | -0.33 | -0.31 | 0.02 | 6.06% |
| 2023-08-14 | 2023-06 | -0.35 | -0.28 | 0.07 | 20.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-12 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-13 | BIRX DEBORAH L. | Chief Executive Officer | 260.00K | Stock Award(Grant) |
| 2024-03-13 | RYCHLIK RICHARD | Officer | 10.00K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Bank of America Corporation | 634.05K | 1.29M | 1.75% |
| 2024-09-29 | Vanguard Group Inc | 225.29K | 459.61K | 0.62% |
| 2024-09-29 | Geode Capital Management, LLC | 107.07K | 218.43K | 0.30% |
| 2024-09-29 | Edgewood Management Llc | 100.00K | 204.01K | 0.28% |
| 2024-09-29 | Bridgeway Capital Management, Inc. | 75.38K | 153.79K | 0.21% |
| 2024-09-29 | Renaissance Technologies, LLC | 46.50K | 94.86K | 0.13% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 115.30K | 235.23K | 0.32% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 106.02K | 216.29K | 0.29% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 66.38K | 135.43K | 0.18% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 59.68K | 121.75K | 0.16% |
| 2024-10-30 | iShares Micro Cap ETF | 21.35K | 43.56K | 0.06% |
| 2024-10-30 | Fidelity Total Market Index Fund | 17.47K | 35.64K | 0.05% |
Split
| Split | Date |
|---|---|
| 1 : 14 | 2019-05-10 |
| 1 : 10 | 2017-04-25 |
| 1 : 50 | 2015-08-07 |
| 1 : 10 | 2006-05-11 |
| 0.1 : 1 | 2006-05-10 |